|
PAT. NO. |
Title |
| 1 |
6,001,852 |
Clioquinol
for the treatment of Alzheimer's disease |
| 2 |
6,001,651 |
Antisense
modulation of LFA-3 |
| 3 |
5,998,583 |
BH3
interacting domain death agonist |
| 4 |
5,998,408 |
Triterpene
derivatives with immunosuppressant activity |
| 5 |
5,998,206 |
Antisense
inhibiton of human G-alpha-12 expression |
| 6 |
5,998,159 |
Methods
for screening for antibiotics |
| 7 |
5,998,148 |
Antisense
modulation of microtubule-associated protein 4 expression |
| 8 |
5,997,898 |
Stabilized
compositions of fluorinated amphiphiles for methods of therapeutic
delivery |
| 9 |
5,994,323 |
Pharmaceutical
compositions comprising clioquinol in combination with vitamin B12 and
therapeutic and prophylactic uses thereof |
| 10 |
5,993,787 |
Composition
base for topical therapeutic and cosmetic preparations |
| 11 |
5,990,096 |
Formulations
containing hyaluronic acid |
| 12 |
5,989,911 |
Site-specific
synthesis of pseudouridine in RNA |
| 13 |
5,985,875 |
1,2,4-triazine-3,
5-dione derivatives, their production and use thereof |
| 14 |
5,985,855 |
Treatment
of global and focal ischemia using NAALADase inhibitors |
| 15 |
5,985,842 |
Boron
compounds/complexes to control hair growth, and methods of use |
| 16 |
5,985,664 |
Antisense
modulation of Sentrin expression |
| 17 |
5,985,663 |
Antisense
inhibition of interleukin-15 expression |
| 18 |
5,985,558 |
Antisense
oligonucleotide compositions and methods for the inibition of c-Jun and
c-Fos |
| 19 |
5,985,309 |
Preparation
of particles for inhalation |
| 20 |
5,981,732 |
Antisense
modulation of G-alpha-13 expression |
| 21 |
5,981,603 |
Antiviral
agents |
| 22 |
5,981,568 |
Therapeutic
inhibitor of vascular smooth muscle cells |
| 23 |
5,981,484 |
Antiangiogenic
peptides and methods for inhibiting angiogenesis |
| 24 |
5,980,914 |
Clioquinol
for the treatment of Parkinson's disease |
| 25 |
5,980,898 |
Adjuvant
for transcutaneous immunization |
| 26 |
5,977,341 |
Antisense
modulation of inhibitor-kappa B kinase-beta expression |
| 27 |
5,977,306 |
Parasitic
helminth P39 proteins, and uses thereof |
| 28 |
5,977,131 |
Azaindole-ethylamine
derivatives as nicotinic acetylcholine receptor binding agents |
| 29 |
5,977,107 |
Alkyl,
azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and
the use thereof as glycine receptor antagonists |
| 30 |
5,977,090 |
Pharmaceutical
compositions and methods of treating compulsive disorders using
NAALADase inhibitors |
| 31 |
5,977,088 |
Formulations
containing hyaluronic acid |
| 32 |
5,977,084 |
Self-assembling
polynucleotide delivery method |
| 33 |
5,977,078 |
Inositol
polyphosphate derivatives and methods of using same |
| 34 |
5,976,565 |
Device
for topical treatment of acne and its method of manufacture |
| 35 |
5,976,101 |
Disposable
and/or replenishable transdermal drug applicators and methods of
manufacturing same |
| 36 |
5,972,996 |
4-cyano-4-deformylsordarin
derivatives |
| 37 |
5,972,978 |
Modulators
of molecules with phosphotyrosine recognition units |
| 38 |
5,972,896 |
Antiangiogenic
peptides and methods for inhibiting angiogenesis |
| 39 |
5,972,705 |
Sequence-specific
methylation of ribonucleic acid |
| 40 |
5,969,135 |
Oligonucleotide
analogs with an amino acid or a modified amino alcohol residue |
| 41 |
5,968,921 |
Compositions
and methods for promoting nerve regeneration |
| 42 |
5,968,780 |
Dendritic
cell-derived growth factor |
| 43 |
5,968,547 |
Method
of providing sustained analgesia with buprenorphine |
| 44 |
5,965,612 |
4-cyano-4-deformylsordaricin
derivatives |
| 45 |
5,965,536 |
Methods
of inhibiting CXC intercrine molecules |
| 46 |
5,965,157 |
Method
to provide for production of hair coloring pigments in hair follicles |
| 47 |
5,962,673 |
Antisense
modulation of inhibitor-kappa B kinase-alpha expression |
| 48 |
5,962,521 |
Hydroxamic
acid derivatives |
| 49 |
5,962,433 |
Topical
composition containing hyaluronic acid and NSAIDS |
| 50 |
5,959,097 |
Antisense
modulation of MEK2 expression |